News | April 30, 2026
Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout
The agreement could rise to $900 million if key commercial milestones are met
The agreement could rise to $900 million if key commercial milestones are met
The Danish biotech company confirmed the global study will begin in the second half of 2026
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Extending production capabilities to the Americas helps reduce labor costs and inventory complexity for nutraceuticals and other industries while maintaining superior moisture control
Aims to boost speed & precision in patient care
CLIRNET plans to expand globally and improve how medical knowledge is shared and used in practice
Subscribe To Our Newsletter & Stay Updated
